Search

Your search keyword '"RICOVER-60"' showing total 3 results
Start Over Descriptor "RICOVER-60"
3 results on '"RICOVER-60"'

1. Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20+ B-cell lymphoma.

Author

Reichwagen, Annegret, Ziepert, Marita, Kreuz, Markus, Gödtel-Armbrust, Ute, Rixecker, Tanja, Poeschel, Viola, Reza Toliat, Mohammad, Nürnberg, Peter, Tzvetkov, Mladen, Deng, Shiwei, Trümper, Lorenz, Hasenfuss, Gerd, Pfreundschuh, Michael, and Wojnowski, Leszek

Abstract

Aim: To identify gene variants responsible for anthracycline-induced cardiotoxicity. Patients & methods: Polymorphisms of the NADPH oxidase subunits and of the anthracycline transporters ABCC1, ABCC2 and SLC28A3 were genotyped in elderly patients (61-80 years) treated for aggressive CD20+ B-cell lymphomas with CHOP-14 with or without rituximab and followed up for 3 years. Results: The accumulation of RAC2 subunit genotypes TA/AA among cases was statistically significant upon adjustment for gender, age and doxorubicin dose in a multivariate logistic regression analysis (OR: 2.3, p = 0.028; univariate: OR: 1.8, p = 0.077). RAC2 and CYBA genotypes were significantly associated with anthracycline-induced cardiotoxicity in a meta-analysis of this and a similar previous study. Conclusion: Our results support the theory that NADPH oxidase is involved in anthracycline-induced cardiotoxicity. Original submitted 9 July 2014; Revision submitted 19 December 2014 [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

2. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial

Author

Ileana Baldi, Umberto Ricardi, Annalisa Chiappella, Francesco Merli, Armando López-Guillermo, Franco Cavalli, Annarita Conconi, Andreas H. Sarris, Henry L. Gomez, Maurizio Martelli, Chiara Bottelli, Mary Gospodarowicz, Sergio Storti, Emanuele Zucca, Umberto Vitolo, Vincenzo Pavone, Andrés J.M. Ferreri, Monica Balzarotti, Domenico Novero, Lorella Orsucci, and Giovanni Martinelli

Subjects
Male, Cancer Research, Pathology, CHOP, Central Nervous System Neoplasms, Antibodies, Monoclonal, Murine-Derived, PROGNOSTIC-FACTORS, Prednisone, MALIGNANT-LYMPHOMA, Antineoplastic Combined Chemotherapy Protocols, Medicine, Prospective Studies, ELDERLY-PATIENTS, Middle Aged, RANDOMIZED CONTROLLED-TRIAL, NON-HODGKINS-LYMPHOMA, CHEMOTHERAPY PLUS RITUXIMAB, RANDOMIZED CONTROLLED-TRIAL, CENTRAL-NERVOUS-SYSTEM, ELDERLY-PATIENTS, MALIGNANT-LYMPHOMA, PROGNOSTIC-FACTORS, RESPONSE CRITERIA, RECURRENCE, RICOVER-60, Treatment Outcome, Oncology, Vincristine, Rituximab, Lymphoma, Large B-Cell, Diffuse, medicine.drug, Adult, medicine.medical_specialty, Cyclophosphamide, Drug-Related Side Effects and Adverse Reactions, RICOVER-60, Urology, Testicular Neoplasms, Chemoimmunotherapy, Humans, NON-HODGKINS-LYMPHOMA, CHEMOTHERAPY PLUS RITUXIMAB, RECURRENCE, Aged, RESPONSE CRITERIA, business.industry, CENTRAL-NERVOUS-SYSTEM, CNS Prophylaxis, medicine.disease, Survival Analysis, Surgery, Lymphoma, First line treatment, Methotrexate, Doxorubicin, business, Diffuse large B-cell lymphoma
Abstract

Purpose Primary testicular lymphoma (PTL) has poor prognosis with failures in contralateral testis, CNS, and extranodal sites. To prevent these events, we designed an international phase II trial (International Extranodal Lymphoma Study Group 10 [IELSG-10]) that addressed feasibility and activity of conventional chemoimmunotherapy associated with CNS prophylaxis and contralateral testis irradiation. The trial was conducted by the IELSG and the Italian Lymphoma Foundation. Patients and Methods Fifty-three patients (age 22 to 79 years) with untreated stage I or II PTL were treated with six to eight courses of rituximab added to cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 21 days (R-CHOP21); four doses of intrathecal methotrexate (IT-MTX) and radiotherapy (RT) to the contralateral testis (30 Gy) for all patients and to regional lymph nodes (30 to 36 Gy) for stage II disease. Results All patients received R-CHOP21, 50 received CNS prophylaxis, and 47 received testicular RT. With a median follow-up of 65 months, 5-year progression-free survival and overall survival rates were 74% (95% CI, 59% to 84%) and 85% (95% CI, 71% to 92%), respectively. Ten patients relapsed or progressed: two in lymph nodes, five in extranodal organs, and three in the CNS. The 5-year cumulative incidence of CNS relapse was 6% (95% CI, 0% to 12%). No contralateral testis relapses occurred. Ten patients died: lymphoma (n = 6), secondary leukemia (n = 2), heart failure (n = 1), and gastric cancer (n = 1). Grade 3 to 4 toxicities were neutropenia, 28%; infections, 4%; and neurologic, 13%. No deaths occurred as a result of toxicity. Conclusion This international prospective trial shows that combined treatment with R-CHOP21, IT-MTX, and testicular RT was associated with a good outcome in patients with PTL. RT avoided contralateral testis relapses, but CNS prophylaxis deserves further investigation.

Published
2011

3. Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma.

Author

Reichwagen A, Ziepert M, Kreuz M, Gödtel-Armbrust U, Rixecker T, Poeschel V, Reza Toliat M, Nürnberg P, Tzvetkov M, Deng S, Trümper L, Hasenfuss G, Pfreundschuh M, and Wojnowski L

Subjects
Aged, Aged, 80 and over, Anthracyclines adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cardiotoxicity pathology, Cyclophosphamide adverse effects, Doxorubicin adverse effects, Female, Genetic Association Studies, Humans, Lymphoma, B-Cell genetics, Male, Middle Aged, Multidrug Resistance-Associated Protein 2, Polymorphism, Single Nucleotide, Prednisone adverse effects, Rituximab adverse effects, Vincristine adverse effects, RAC2 GTP-Binding Protein, Cardiotoxicity genetics, Lymphoma, B-Cell drug therapy, NADPH Oxidases genetics, rac GTP-Binding Proteins genetics
Abstract

Aim: To identify gene variants responsible for anthracycline-induced cardiotoxicity., Patients & Methods: Polymorphisms of the NADPH oxidase subunits and of the anthracycline transporters ABCC1, ABCC2 and SLC28A3 were genotyped in elderly patients (61-80 years) treated for aggressive CD20(+) B-cell lymphomas with CHOP-14 with or without rituximab and followed up for 3 years., Results: The accumulation of RAC2 subunit genotypes TA/AA among cases was statistically significant upon adjustment for gender, age and doxorubicin dose in a multivariate logistic regression analysis (OR: 2.3, p = 0.028; univariate: OR: 1.8, p = 0.077). RAC2 and CYBA genotypes were significantly associated with anthracycline-induced cardiotoxicity in a meta-analysis of this and a similar previous study., Conclusion: Our results support the theory that NADPH oxidase is involved in anthracycline-induced cardiotoxicity. Original submitted 9 July 2014; Revision submitted 19 December 2014.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results